| Literature DB >> 31584946 |
Pei-Ying Kobres1, Jean-Paul Chretien2, Michael A Johansson3, Jeffrey J Morgan4, Pai-Yei Whung5, Harshini Mukundan6, Sara Y Del Valle6, Brett M Forshey7, Talia M Quandelacy3,8, Matthew Biggerstaff9, Cecile Viboud10, Simon Pollett11,12,13.
Abstract
INTRODUCTION: Epidemic forecasting and prediction tools have the potential to provide actionable information in the midst of emerging epidemics. While numerous predictive studies were published during the 2016-2017 Zika Virus (ZIKV) pandemic, it remains unknown how timely, reproducible, and actionable the information produced by these studies was.Entities:
Year: 2019 PMID: 31584946 PMCID: PMC6805005 DOI: 10.1371/journal.pntd.0007451
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1PRISMA flow-chart indicating the number of studies identified, screened, and confirmed for eligibility into this systematic review.
Objectives and study population of eligible studies.
| n | % | |
|---|---|---|
| Total number of studies | 73 | 100 |
| Zika-related phenomenon forecasted or predicted | ||
| Predicted microcephaly burdens | 11 | 15 |
| Guillain-Barré syndrome burden | 3 | 4 |
| Epidemic peak size | 4 | 5 |
| Epidemic peak timing | 4 | 5 |
| Epidemic curve trajectory | 8 | 11 |
| Epidemic final size | 5 | 7 |
| Spatial spread | 25 | 34 |
| Force of infection | 7 | 10 |
| Cost-effectiveness | 2 | 3 |
| Intervention impact | 3 | 4 |
| Case fatality ratio | 0 | 0 |
| Ro or RE | 21 | 29 |
| Sexual transmission risk | 3 | 4 |
| Vector competence / ecology | 9 | 12 |
| Other | 2 | 3 |
| Geographic region in which predictions made | ||
| Africa | 3 | 4 |
| Americas (excluding Continental USA) | 31 | 42 |
| Asia–Pacific | 15 | 21 |
| Continental USA | 7 | 10 |
| Europe | 4 | 5 |
| Global | 18 | 24 |
aDenominator excludes those studies where unable or no basis to judge
bSome studies predicted more than one phenomenon
cIncluded estimates of R0
dEcological determinants of vector minimum abundance rate (n = 1); epidemic size and number of infections at time of first microcephaly case detected (n = 1)
eSome studies included >1 geographic category
Data sources, methodology and reproducibility of eligible studies.
| N | % | |
|---|---|---|
| Data types used | ||
| Case count | 49 | 67 |
| Demographic | 27 | 37 |
| Genomic sequence data | 0 | 0 |
| Climate, meteorological and earth science | 21 | 29 |
| Transport | 14 | 19 |
| Economic | 7 | 10 |
| Vector | 30 | 41 |
| Internet search engine, social media or news-wire scraping data | 5 | 7 |
| Other | 9 | 12 |
| Relevant data made available | ||
| Entirely | 29 | 40 |
| Partially | 27 | 37 |
| Not at all | 16 | 22 |
| Model type(s) used in analysis | ||
| Stochastic | 21 | 29 |
| Deterministic | 56 | 76 |
| Availability of statistical modeling computational code (e.g. R script provided) | ||
| Entirely | 21 | 29 |
| Partly | 7 | 10 |
| Not at all | 45 | 62 |
| Clear and accurate visual display of the model output | ||
| Entirely | 49 | 67 |
| Partly | 20 | 27 |
| Not at all | 4 | 5 |
| Estimates of prediction uncertainty provided (e.g. confidence intervals) provided | ||
| Entirely | 31 | 43 |
| Partly | 13 | 18 |
| Not at all | 28 | 39 |
| Methods presented with a level of detail that allowed the study to be reproduced | ||
| Entirely | 37 | 54 |
| Partially | 28 | 41 |
| Not at all | 4 | 6 |
aDenominator excludes those studies where unable or no basis to judge
bSome studies used multiple data types
cViremia duration and dynamics (n = 3); sexual contact network (n = 2); semen viral persistence (n = 2), non-human primate demographics (n = 1), mammalian diversity (n = 1)
dSome studies used both stochastic and deterministic models
Accessibility, timeliness and other bibliometrics of eligible studies.
| n | % | |
|---|---|---|
| Open access | 68 | 96 |
| Pre-print access | 22 | 30 |
| median | IQR (range) | |
| Journal impact factor | 4.37 | 2.65–7.62 (1.48–79.26) |
| Submission to acceptance time, days | 83 | 44–112 (0–256) |
| Acceptance to publication time, days | 15 | 7–24 (-255–279) |
| Submission to publication time, days | 93.5 | 47–141 (1–389) |
aIncludes non-journal open access websites. Open access defined as able to be viewed without any payment or institutional journal license
bBiorxiv n = 19, ResearchGate n = 1, Bull WHO rapid journal pre-acceptance pre-print n = 2
cNegative values exist as Bull WHO articles published upon receipt (within 24 hrs) and then accepted later
dDenominator may vary in cases where these metrics were unable to be determined
ePublication time based on electronic journal version where available
Fig 2Comparative trends of reported Zika cases in Latin American and publication times of Zika prediction studies.
Zika case counts were obtained from https://andersen-lab.com/ with permission.
Fig 3Comparative trends in publication times of ZIKV prediction studies with and without the use of preprints.
Author affiliation and funding source of eligible studies.
| Affiliation of authors | n | % |
| Academia | 68 | 93 |
| Govt (US) | 14 | 19 |
| Govt (non-US) | 19 | 26 |
| Industry | 4 | 5 |
| NGO | 14 | 19 |
| Other type of organization | 4 | 5 |
| Funding source | n | % |
| USG | ||
| CDC | 1 | 2 |
| DHS | 2 | 4 |
| DoD | 3 | 6 |
| LANL | 1 | 2 |
| NASA | 1 | 2 |
| NIH | 21 | 39 |
| NSA | 2 | 4 |
| NSF | 12 | 22 |
| USAID | 1 | 2 |
| USDA | 3 | 6 |
| Other USG | 1 | 2 |
| Any USG | 27 | 50 |
| Any Non-US Govt | 46 | 85 |
| Any Industry | 3 | 6 |
| Any NGO | 19 | 35 |
| Any international normative body | 6 | 11 |
| Other | 6 | 11 |
aMultiple affiliations associated with some studies
bScientific contracting/consulting (n = 3), spatial epidemiology software (n = 1)
cWorld Health Organization (n = 2), European Centers for Disease Control (n = 1), HealthMap (n = 1)
dMultiple funding streams associated with some studies
eUnable to be determined or unfunded in a number of studies, denominator = 54
fState Dept of Health (TX)
gAcademic intramural funding (n = 5)